These findings suggest that HER2 + IBC tumours have a greater ability to shape the immunosuppressive microenvironment, indicating that antibody-secreting cells with high expression of SOX4 molecules and tumour cells with high expression of PTN molecules need to be considered to develop more targeted therapeutic targets and adjuvant therapeutic regimens for the treatment of HER2 + IBC patients. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.